Woman reading the Dagens Industri newspaper

Press releases

Category
Year

Extraordinary General Meeting in Oncopeptides AB (publ) Regulatory

March 13, 2024
The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Extraordinary General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, SE-111 53 Stockholm, Sweden on Monday 15 April 2024 at 15:00 CEST. Registration for attendees will commence at 14:30 CEST
Read more

Oncopeptides carries out a fully guaranteed rights issue of approximately SEK 300 million to reach profitability during 2026 Regulatory

March 13, 2024
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN ONCOPEPTIDES AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT
Read more

Oncopeptides’ PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration

March 1, 2024
Stockholm – March 1, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that a new article analyzing scientific data on melflufen, marketed in Europe as Pepaxti, was recently published in the peer-reviewed medical journal Clinical Lymphoma, Myeloma & Leukemia. The results provide further evidence that administration via peripheral venous catheter (PVC) is well tolerated with no local infusion-related reactions or new safety signals and may represent an alternative route of administration
Read more

Pepaxti provides sustained health related Quality of Life OCEAN study shows, article published in Haematologica

February 29, 2024
Stockholm – February 29, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that a new article analyzing health-related quality of life in patients treated with melflufen, marketed in Europe as Pepaxti, has been published in Haematologica, a monthly peer-reviewed open access medical journal
Read more

Oncopeptides publishes year-end report 2023 Regulatory

February 27, 2024
Stockholm – February 27, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today publishes the year-end report for 2023
Read more

Oncopeptides receives decision from the U.S. Food and Drug Administration confirming withdrawal of Pepaxto from the U.S. market

February 23, 2024
Stockholm – February 23, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the U.S. Food and Drug Administration (FDA) has made a decision regarding the withdrawal of Pepaxto, which Oncopeptides had appealed
Read more

Oncopeptides receives positive recommendation for Pepaxti by Spanish Pricing Authority Regulatory

February 23, 2024
Stockholm, February 23, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the Spanish Drug Pricing Authority (CIPM) has published a positive recommendation for the pricing of melflufen, branded in Europe as Pepaxti
Read more

Invitation to presentation of the year-end report 2023

February 21, 2024
Stockholm – February 21, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, will publish the report for the fourth quarter and the 2023 year-end report, at 08:00 (CET) on February 27, 2024. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session on February 27 at 09:00 CET
Read more

Oncopeptides ensures five years extended market exclusivity for Pepaxti in Europe Regulatory

February 15, 2024
Stockholm, February 15, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that it will receive an extension of a key patent ensuring market exclusivity for melflufen, marketed in Europe as Pepaxti, in Europe until 2037, an extension of five years
Read more

Update on the Type II application process

December 15, 2023
Stockholm – December 15, 2023 – Oncopeptides today announces that the European Commission has decided to formally approve the company’s application to the European Medicines Agency (EMA) for an extended indication for Pepaxti into earlier lines. The previously communicated decision by Oncopeptides to opt out of the process to extend the indication remains
Read more